Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04037449
Other study ID # 19/35
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 30, 2020
Est. completion date November 30, 2022

Study information

Verified date November 2020
Source Consorci Sanitari Integral
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background Severe abdominal pain is a hallmark of acute pancreatitis (AP). A control pain is often difficult. Transversus Abdominis Plane (TAP) block has been used in pain control in patients with exacerbation of chronic pancreatitis. Objectives To evaluate the effect of Bilateral Blockade of the Abdominal Transverse Muscle Plane (TAP Block) in the analgesic control of patients with acute pancreatitis; compared to standard intravenous analgesia. Methods A randomized controlled trial of parallel groups will be conducted. The Study will have a multicenter development. Study population: Adult patients admitted for episode of AP, with uncontrolled pain (visual analogue scale (VAS) equal to or greater than 5 after the administration of standard analgesia. Randomization Groups: Group A: Patients who will undergo TAP block as analgesic procedure added to standard analgesia. Group B: Patients to whom morphine 2 mg / ev will be administered as analgesic procedure added to standard analgesia. Timing of pain determination (Visual Analogue Scale, VAS): - Before conventional analgesia - Immediately before Randomization - 15 minutes after the administration of the analgesic treatment object of the study. - One hour after the procedure. - Every 8 hours, during the next 4 days or until discharge of the patient. - Whenever the patient needs a dose of supplemental rescue analgesia. Analysis of data All results will be evaluated according to the initial "intention to treat". There will be a blinded assessment of the results after the last patient in the trial has completed the follow-up. The results will be presented as relative risks with their corresponding confidence intervals. P <0.05 will be considered statistically significant. In case of imbalance between the two treatment groups, a multivariate logistic regression is used to correct possible confounding factors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 44
Est. completion date November 30, 2022
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Diagnosis of acute pancreatitis according to modified Atlanta criteria . - Patients with the ability to understand the VAS scale and express their level of pain. - Patients over 18 years old. - Uncontrolled pain, with VAS = 5 after the administration of standard analgesia. - Material and technical possibility of performing the TAP technique immediately after randomization. - Informed consent of the participating patients for inclusion in the study. - Informed consent of the participating patients for the administration of TAP. - Normality of coagulation levels Exclusion Criteria: - Patients with American Society of Anaesthesia (ASA) levels IV and V - Patients with chronic pancreatitis - Pregnancy - Patients with chronic treatment with morphic medication

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
TAP block
With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
Other:
Conventional analgesia
Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours. Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Consorci Sanitari Integral

Outcome

Type Measure Description Time frame Safety issue
Primary Change of pain levels (VAS) after the intervention To assess the VAS value in order to measure the time elapsed from the intervention until reaching the appropriate level of analgesic efficacy. Analgesic efficacy is defined as the patient having a pain VAS value = 3. Baseline (Before the intervention), 15 minutes after the intervention, 1 hour after the intervention, 8 hours after the intervention, 16 hours after the intervention, 24 hours after the intervention
Secondary Complications Complications related to the analgesic technique used, either by the administration procedure or as a side effect through study completion, an average of 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Recruiting NCT05572788 - Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts N/A
Completed NCT03642769 - Lactated Ringer's Versus Normal Saline for Acute Pancreatitis N/A
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT04570852 - Acute Pancreatitis Targets (APT) Study N/A
Recruiting NCT03686618 - Secretin for Acute Pancreatitis Phase 2
Not yet recruiting NCT03740685 - Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
Completed NCT03342716 - Resolution of Organ Injury in Acute Pancreatitis - RESORP
Not yet recruiting NCT03342807 - Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis Phase 4
Terminated NCT02959112 - Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography N/A
Recruiting NCT05381428 - Prophylaxis of Post-ERCP Acute Pancreatitis Phase 3
Active, not recruiting NCT05955235 - A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
Recruiting NCT05160506 - Corticosteroids to Treat Pancreatitis Phase 2
Not yet recruiting NCT03082469 - Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal Phase 4
Completed NCT03672422 - Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
Completed NCT00490386 - Helicobacter Pylori and Acute Alcohol Induced Pancreatitis N/A
Completed NCT04188990 - Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition N/A
Active, not recruiting NCT04743323 - A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis
Completed NCT03829085 - Study of the Diet in Patients With the Diagnostic of Acute Pancreatitis N/A
Not yet recruiting NCT04760847 - Intermittent Fasting for Pancreatitis N/A